Reducing Cardiovascular Burden in Diabetes 2 – Use of novel drugs
Prof. Stephen Fava, Consultant Diabetologist & Endocrinologist, and Head of the Diabetes and Endocrine Unit at Mater Dei Hospital, discusses the use and effectiveness of novel drugs in the reduction of cardiovascular burden in diabetes. This discussion will follow the presentation on reduction of modifiable risk factors, also by Prof. Fava.
- The evidence for GLP1Ra, SGLT2i & others in cardiovascular protection
Accessing this module requires a login. Please enter your credentials below!